WO1998056928A1 - Production accrue de proteines au moyen de proteines du type chaperone - Google Patents

Production accrue de proteines au moyen de proteines du type chaperone Download PDF

Info

Publication number
WO1998056928A1
WO1998056928A1 PCT/NL1998/000335 NL9800335W WO9856928A1 WO 1998056928 A1 WO1998056928 A1 WO 1998056928A1 NL 9800335 W NL9800335 W NL 9800335W WO 9856928 A1 WO9856928 A1 WO 9856928A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
polypeptide
chaperone
host cell
proteins
Prior art date
Application number
PCT/NL1998/000335
Other languages
English (en)
Inventor
Michiel Marie Harmsen
Bernard De Geus
Original Assignee
Stichting Instituut Voor Dierhouderij En Diergezondheid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Instituut Voor Dierhouderij En Diergezondheid filed Critical Stichting Instituut Voor Dierhouderij En Diergezondheid
Priority to AU80407/98A priority Critical patent/AU8040798A/en
Priority to EP98928658A priority patent/EP0980436A1/fr
Publication of WO1998056928A1 publication Critical patent/WO1998056928A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6483—Chymosin (3.4.23.4), i.e. rennin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23004—Chymosin (3.4.23.4), i.e. rennin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag

Definitions

  • the invention relates to the production of recombinant proteins that are expressed in heterologous host cells and to methods to increase production levels of these proteins.
  • Expression systems which can be in vi tro expression systems or in vivo expression systems comprising hosts cells, are frequently used for the production or expression of a foreign polypeptide or protein originate from at least five kingdoms: such as (1) prokaryotes, such as Escheri chia coli (2) fungi, including the yeasts, such as Saccharomyces cerevisiae, and the filamentous fungi, such as Aspergillus awamori , (3) mammals, including intact organisms such as Bos tauris , and various mammalian cell lines originating from several species, (4) insect cell lines, such as Spodoptera frugiperda , and (5) plants (Hodgson, 1993, Bio/Technology 11: 887—893).
  • prokaryotes such as Escheri chia coli
  • yeasts such as Saccharomyces cerevisiae
  • filamentous fungi such as Aspergillus awamori
  • mammals including intact organisms such as Bos tauris
  • Hosts from the first two kingdoms can most easily be genetically modified and have a potential for high- level polypeptide or protein production at low cost.
  • the success with which foreign proteins can be produced in a heterologous organism is highly variable.
  • Simple proteins can often be expressed reasonably well in host cells derived from for instance the prokaryotes or the yeasts and fungi, however, more complicated proteins are often refractory to expression in these simple host cells, and often require expression in the more complicated insect, plant or animal cell systems, or even require expression in very specialized cells or even in whole organisms which comprise the specialized cells and cell systems necessary for proper expression and processing of the wanted protein.
  • Heterologous (over) expression comprises several steps which all have a distinct impact on the success with which a foreign protein can be produced.
  • the gene encoding the protein of interest or wanted protein must be isolated from the original host.
  • this gene must be redesigned and inserted into a vector suitable for expression in the heterologous host. This often includes replacement of the transcription and translation signals of the pertinent gene by sequences which originate from the heterologous host in order to obtain high levels of mRNA which can be translated. This may also include removal of introns and change of codon usage. With current state of the art of recombinant DNA technology it is possible to perform these first two steps for any protein (e.g. see the reviews of Romanos et al., 1992, Yeast 8: 423-488; Wall and Pluckthun, 1995, Curr. Opin. Biotechnol. 6: 507-516) .
  • the heterologous protein must contain the appropriate targeting signals for directing the protein to the desired subcellular compartment.
  • Especially targeting to the secretory pathway is frequently used since the purification of the foreign protein once it is secreted into the culture medium is relatively simple. For this purpose it may be necessary to remove the original targeting signals and introduce new targeting signals. With current knowledge of targeting signals this can also be performed for any protein.
  • the protein must be post-translationally modified in a correct manner.
  • N-glycosylation of proteins is an important modification in this respect since many commercially interesting proteins need to be M- glycosylated correctly to attain biological activity. Since N-glycosylation of proteins does not occur in prokaryotes and occurs in a different manner in the cells or organisms originating from the various kingdoms, the production of mammalian proteins, which form the majority of commercially interesting proteins-, in many of these organisms often results in absent or improper iV-glycosylation.
  • foldases Protein folding in vivo (in the cell) is now known to be assisted by a diverse set of naturally occurring (native) proteins collectively known as foldases (e.g. see reviews by Gething and Sambrook, 1992, Nature 355: 33-45; Hartl, 1996, Nature 381: 571-580).
  • a major subgroup of the foldases are the molecular chaperones, which are defined as a group of unrelated classes of proteins that bind to and stabilize an otherwise unstable conformer or immature form of another protein and by controlled binding and release facilitate its correct fate in vivo, be it folding, oligomeric assembly, transport to a particular subcellular compartment, or disposal by degradation.
  • Gram negative prokaryotes such as E . coli contain two compartments which are important in this respect: the cytosol and the periplasmic space. Eukaryotes contain several compartments where protein folding occurs, of which the most important ones are (1) the cytosol, (2) the endoplasmic reticulum (ER) , (3) mitochondria and (4) chloroplasts .
  • the cytosol of both prokaryotes and eukaryotes is a relatively reducing environment as compared to the ER.
  • Chaperones can bind to an immature form of a specific protein and shield the protein from the cellular environment, thereby inducing or catalysing proper folding and conformation of to-be-expressed proteins, and preventing mis-folding and aggregation.
  • proteins with such activity can be found in many protein families which have different functions, such as the Hsp60, Hsp70, Hsp90, Bip, chaperonin and Calnexin. All these foldases co-operate in a complex interplay that is regulated by other proteins during protein folding.
  • Foreign proteins can occasionally be produced in a mis- folded state in a heterologous host and subsequently isolated after e.g. disruption of the host cells. Also, occasionally, a mis-folded protein is secreted from the host cell despite its misfolded state. Protocols have been designed to refold the misfolded proteins in vi tro, however, this is a cumbersome process that is costly and does not result in a high yield of the wanted protein. Several of the in vi tro folding protocols entail the use of antibodies as the in vi tro folding agent.
  • heterologous proteins are usually expressed at a high level, which results in overloading of an already in itself not well-suited chaperone machinery.
  • foldase itself may misfold upon over-expression, either due to its heterologous nature whereby the chaperone-like properties of the foldase do not correspond to the requirements of the host cell, or due to its over-expression.
  • the particular foldase chosen for over-expression does not function for the heterologous protein.
  • protein folding is assisted by a complex machinery consisting of many foldases it is impossible to stimulate the process by simply over- expressing a single and ill-fitting component.
  • the present invention provides a method of protein production in a expression system by providing a chaperone- like protein also referred to as design chaperone.
  • the invention further provides a chaperone-like protein with at least one binding site with binding activity for at least one immature form of a polypeptide for which it originally had no, less or different binding activity.
  • a chaperone-like protein is a non-native chaperone or other binding protein specifically devised and brought into being to be capable of the (transient) binding with a protein that is done in nature by a chaperone.
  • a chaperone-like protein is selected to have a distinct substrate specificity and other chaperone-like properties and is deliberately generated and tailored via recombinant techniques to have the capacity to cause proper folding, transporting or secretion of a protein that e.g. is being expressed in an expression system. Binding of a chaperone-like protein to the wanted polypeptide takes place by the more-or-less transient formation of multiple non- covalent bonds between the two proteins. Although the attractive forces involved in these bonds are weak by comparison with covalent bonds, the multiplicity of the bonds leads to a often considerable binding energy.
  • binding proteins a wide array of proteins is known in the art, such as receptor molecules, chaperone proteins, polyclonal or monoclonal (synthetic) antibodies, minibodies, binding peptides, phage' antibodies derived via phage display techniques, single-chain antibody-variable fragments (scVF's), heavy-chain antibody fragments, in general all proteins belonging to the immunoglobuline superfamily (including bacterial proteinases, MHC molecules, T-cell receptors) , and so on.
  • a chaperone-like protein generally has a narrow band of specificity, in that it is specifically reactive with the polypeptide for which it is designed and with structurally, functionally or antigenically related proteins.
  • the invention provides a method to express a wanted polypeptide encoded by a nucleic acid sequence or molecule present in a host cell which additionally comprises a chaperone-like protein capable of specific binding with said wanted polypeptide.
  • Said chaperone-like protein used in the method provided by the invention comprises at least one binding site reactive with the wanted polypeptide.
  • Such a binding site of a chaperone-like protein provided by the invention can be derived from a wide array of sources.
  • the invention for example provides a chaperone-like protein comprising a binding site that is derived from a (synthetic) peptide sequence that is reactive with the wanted polypeptide.
  • Such a peptide can be selected by various methods known in the art, such as PEPSCAN methods, applied molecular evolution methods, PEPSCAN replacement mapping, and so on.
  • the invention for example also provides a chaperone- like protein comprising a binding site that is derived from naturally occurring binding proteins such as enzymes, receptor molecules, cell surface proteins, chaperones, transfer proteins, and so on.
  • a preferred embodiment of the invention entails the use of a chaperone-like protein that comprises a binding site that is derived from an antibody, an antibody fragment, a single-chain antibody fragment, or from any the variable regions of the heavy and/or light chain of antibodies.
  • binding sites derived from heavy-chain antibody fragments of camelids are used, but it is within the ordinary skills of those working in the field of immunology to select an antibody derived from an appropriate species, varying from poultry to sharks, providing (a) binding site(s) for use in a chaperone-like protein according to the invention.
  • a chaperone-like protein provided by the invention is instrumental in causing improved folding of the protein for which it bears specific binding activity.
  • the invention also provides an expression system provides with a chaperone-like protein.
  • Such an expression system can be an in vivo system, using host cells of various origin, or an in vi tro system, using e.g.
  • lysates of various host cells such as reticulocyte lysates or wheat germ extracts in which in vi tro (transcription-) translation can occur.
  • the chaperone-like protein enhances correct folding of the expressed polypeptide.
  • a chaperone-like protein when present in a host cell expressing a polypeptide for which it bears specific binding activity, a chaperone-like protein is instrumental in causing improved routing through the cell and an increase of secretion of the properly folded polypeptide from said host cell.
  • the invention also provides a nucleic acid molecule or molecules encoding a chaperone-like protein.
  • nucleic acid molecule provided by the invention can be both DNA or RNA, be it single or double stranded, and can be subjected to recombinant techniques known in the art.
  • nucleic acid molecules can additionally comprise a nucleic acid sequence encoding the wanted polypeptide.
  • the invention also provides vectors, expression systems and host cells comprising such a nucleic acid.
  • Such a nucleic acid molecule can for example be place into an expression vector.
  • Such a vector may be replicable or non-replicable, and can be integrated partly or whole in the chromosomal DNA of the host cell or the expression system.
  • such a vector may comprise the sequences encoding both the wanted polypeptide and the chaperone-like protein.
  • a vector can easily be swapped from host cell to e.g. an in vi tro expression system, or to yet another host cell, and vice versa.
  • a preferred embodiment of the invention is a vector containing sequences allowing for controlled expression of the chaperone-like protein and/or the wanted polypeptide.
  • the invention provides host cells comprising a nucleic acid encoding a chaperone-like protein which is preferably linked to a promotor, enhancer, upstream control elements, transcription factors, repressor binding sites, polyadenylation sites, initiation site and so on, thereby e.g. facilitating constitutive or, alternatively, inducible expression of the chaperone-like protein.
  • the invention thus allows various modes of expression of the chaperone-like protein, in relation to the time and mode of expression of the wanted polypeptide.
  • the invention for example provides a method whereby the chaperone-like protein is being expressed in advance to, or at the same time as, the expression of the wanted polypeptide, thereby making functional chaperone-like protein available in the host cell at the times most needed, namely when the wanted polypeptide is being produced.
  • the invention also provides a method of protein production whereby co-expressing a chaperone-like protein causes improved folding and/or secretion of a protein that is expressed in an expression system.
  • the invention provides a method whereby the chaperone-like protein is being co- expressed together with its protein, which is either autogenous or heterogenous to the expression system.
  • a preferred embodiment of the invention provides a method to produce a protein in a heterologous expression system whereby a chaperone-like protein is being co-expressed, said chaperone-like protein being capable of facilitating proper folding and/or secretion of the protein.
  • the method provides host cells expressing a foreign protein and equipped with a nucleic acid molecule encoding a chaperone-like protein according to the invention. In the host cells provided by the invention the folding of the wanted foreign protein is helped by the specific chaperone-like protein, preventing the formation of accumulating aggregates of misfolded protein and thereby easing the routing and secretion of the foreign protein out of the cell.
  • Host cells provided by the invention comprise a nucleic acid molecule or molecules encoding a chaperone-like protein, which in one embodiment of the invention can be expressed transiently, in another embodiment constitutively . In yet another embodiment of the invention the expression of the chaperone-like protein is inducible. Furthermore, host cells provided by yet another embodiment of the invention comprise multiple copies of a nucleic acid molecule or molecules encoding one or more chaperone-like proteins.
  • said nucleic acid molecule encoding a chaperone-like protein can be integrated in the genome of the host cell, or alternatively, can be part of a vector (such as a plasmid, or shuttle vector or bacteriophage or cosmid or virus) with which the host cell has been infected or transformed.
  • the invention provides host cells comprising a chaperone-like protein.
  • host cells can be prokaryotic, for example bacteria belonging to the genera Escherichia , Bacillus , Streptomyces and La ctobacillus .
  • the invention also provides other host cells comprising a chaperone-like protein, e.g, wherein the host cell is a fungus, for example selected from the group of yeasts belonging to the genera Saccharomyces , Kl uyveromyces , Hansenula , Pichia , Debaryomyces , Yarrowia , Candida and
  • Another host cell according to the invention is an insect cell or a plant cell, especially when the wanted polypeptide undergoes pots-translational modifications which call for the use of insect cells or plant cells.
  • a preferred embodiment of the invention entails the expression of a mammalian polypeptide in relatively simple expression systems that are now equipped with a functional chaperone-like protein specific for the wanted polypeptide.
  • the invention provides a method for the expression, folding, transportation and/or secretion of a wide array of wanted polypeptides, varying from enzymes, hormones, cytokines, growth factors, antibodies, antigens for vaccines and diagnostic tests, and any other polypeptide that may be expressed in expression systems for commercial purposes.
  • the invention provides a method for expressing a polypeptide comprising translating said polypeptide and providing a chaperone-like protein according to the invention.
  • the invention provides a method for expressing a polypeptide comprising using an expression system or a host cell provided by the invention.
  • the invention provides a method for transporting a polypeptide in a host cell or for secreting a polypeptide from a host cell comprising translating said polypeptide in said host cell and further comprising providing a chaperone-like protein according to the invention or using a nucleic acid, vector, expression system or host cell according to the invention, allowing for the formation of complexes between the chaperone-like protein and (an immature form) of said polypeptide.
  • the invention provides a method according to any wherein said chaperone-like protein is being expressed prior to and/or during the expression of said polypeptide, and, in a preferred embodiment, a method according wherein said chaperone-like protein is being co- expressed with said polypeptide.
  • the invention provides a method for enhancing correct polypeptide folding comprising creating a mixture which at least comprises said polypeptide and a chaperone-like protein according to the invention.
  • the method according to the invention is applicable to a polypeptide of mammalian origin and/or to a polypeptide which is post-translationally modified.
  • the invention provides a method wherein the polypeptide is (pro) chymosine .
  • the invention also provides a chaperone-like protein-polypeptide complex which is obtainable by a method provided by the invention. Such complexes can be isolated from the expression system with methods shown in the experimental part of the description.
  • proteins (or peptides) with binding characteristics often come in pairs, for example binding between chaperone and corresponding protein, but also for example between ligand and receptor, or peptide and MHC/HLA molecules, or between antigen and antibody. Binding in itself can range from very aspecific on the one hand to very specific on the other hand, as for example is demonstrated when one compares weak hydrophobic interactions between peptide sequences on the one hand with the complex interactions as seen with antibody-antigen binding on the other hand. Binding is dependent on the binding site(s) .
  • a binding site can be a simple linear peptide sequence, or a complex of two or more linear sequences comprising a conformational binding site.
  • Another characteristic of protein binding is that it can range from having very low to very high affinity, depending on the ⁇ fit' of the binding site, or binding interaction, or binding motif, or, for example with antigen-antibody binding, the epitope-paratope interaction, between the corresponding peptide sequences and conformational shapes of the two molecules.
  • a chaperone-like protein as provided by the invention is generated by processes and methods from nucleic acid recombinant technology or protein engineering, for example processes resembling DNA or RNA shuffling or random rearrangements (including mutations, deletions and insertions) or recombinations of DNA or RNA, but can also entail rearrangements or recombinations or mutations, insertions or deletions with or in (parts of) a peptide sequence (constituting a binding motif or paratope or the like) derived from known binding proteins, and such processes each result in a large, in essence unlimited, range or repertoire of (potential) chaperone-like proteins, from which repertoire each resulting chaperone may be specifically well-suited to function in yet another specific heterologous expression system as yet another chaperone for yet another specific protein.
  • a chaperone-like protein is for instance generated in host cells such as yeast cells (but libraries of cells of other expression systems can also be used) by the generation of host cell banks or libraries in which a nucleic acid sequence (encoding a binding protein or potential chaperone- like protein) is rearranged or shuffled by techniques for example comprising in vi tro homologous recombination of pools of selected genes (mutant genes and non-mutant genes) by random fragmentation and PCR re-assembly (Stemmer, PNAS 91, 10747-10751) , followed by transformation of the host cells with reassembled fragments.
  • host cells such as yeast cells (but libraries of cells of other expression systems can also be used) by the generation of host cell banks or libraries in which a nucleic acid sequence (encoding a binding protein or potential chaperone- like protein) is rearranged or shuffled by techniques for example comprising in vi tro homologous recombination of pools of selected genes (mutant genes and non-mutant genes)
  • Another method to generate a chaperone-like protein is by expressing the peptides or proteins encoded by rearranged nucleic acid sequences (possibly derived from a nucleic acid sequence encoding a binding protein) in a phage display system.
  • This has the added advantage that, depending on the wanted affinity of the chaperone-like protein, phage populations can be selected that are enriched for phages expressing the wanted chaperone- like protein, based on the fact that some phages in the library will react with higher affinity with the corresponding protein than other phages.
  • Yet another possible method to generate a library of host cells comprising a chaperone-like protein specific for a corresponding protein uses hosts cells comprising nucleic acid molecules of a naturally occurring chaperone, or comprising nucleic acid molecules of an earlier designed or selected chaperone-like protein.
  • Such host cells are modified or transformed by e.g. homologous recombination techniques as above, or directly in vivo, with reshuffled or rearranged or in any other way modified nucleic acid, replacing or modifying the known nucleic acid molecules.
  • the invention also provides a method to obtain a chaperone-like protein and host cells comprising a chaperone-like protein by selection for the chaperone-like protein induced rescue of host cells expressing the polypeptide of interest that is inhibitory to growth of these cells, by generating a pool of rearranged nucleic acid molecules encoding binding proteins potentially reactive with said polypeptide, followed by introduction of said pool into host cells capable of producing said polypeptide followed by selecting said transformed host cells for improved growth rates.
  • the invention provides a method for obtaining a transformed host cell comprising a chaperone-like protein comprising transforming a host cell with a nucleic acid encoding a polypeptide to be expressed, or selecting a host cell expressing said polypeptide, further comprising transforming a host cell expressing said polypeptide with a nucleic acid encoding a chaperone-like protein.
  • Such a method provided by the invention to obtain a transformed host cell comprising a functional chaperone-like protein comprises selecting a polypeptide to be expressed in said host cell and transforming a host cell with nucleic acid encoding said polypeptide, or, selecting a host cell capable of expressing said polypeptide, transforming a bank of host cells capable of expressing said polypeptide with a variant nucleic acid molecule derived from a pool of nucleic acid molecules encoding a potential chaperone-like protein, selecting the thus transformed host cells for improved growth rates and/or increased expression, folding or secretion of said polypeptide.
  • the invention also provides the use of a host cell comprising a chaperone-like protein in the production of a polypeptide, and also provides a chaperone-like protein obtainable from a host cell.
  • a host cell comprising a chaperone-like protein in the production of a polypeptide
  • a chaperone-like protein obtainable from a host cell.
  • These can also be used in a method for improving or enhancing correct in vi tro or in vivo folding of a polypeptide, by creating a mixture which at least comprises a chaperone-like protein provided by the invention and (an immature form of) a polypeptide, or in a method for increasing secretion of a polypeptide from a host cell.
  • the invention is further illustrated by examples in the experimental part of the description without being limited thereto.
  • Mature chymosin is an aspartyl protease that is responsible for the coagulation of milk proteins in the fourth stomach of unweaned calves. It has been a prime target for production in micro-organisms because of its use in cheese production.
  • the mRNA encodes the precursor polypeptide preprochymosin, which is converted into the inactive zymogen prochymosin by removal of the signal peptide in the ER.
  • Native prochymosin is autocatalytically activated to chymosin at low pH.
  • prochymosin in yeast (Harmsen, 1995, PhD thesis, Vrije Universiteit , Amsterdam; Harmsen et al . , 1996, Appl. Microbiol. Biotechnol . 46:365-370) as a fusion protein consisting of the signal peptide derived from the yeast invertase protein and prochymosin using a suitable plasmid (pSY78) .
  • This plasmid is an integrative E. coli -yeast shuttle vector containing a TRP1 gene as the selection marker and an expression cassette consisting of the fusion protein flanked by the GAL7 promoter and the terminator from the PGK1 gene.
  • This plasmid was integrated at the TRP1 locus of strain W303-1A in single copy after linearization with EcoRV, which cuts in the marker gene, resulting in strain MR16.
  • Prochymosin is inefficiently secreted ( ⁇ 1%) by strain MR16.
  • the intracellularly accumulated prochymosin is not activatable, suggesting that it is misfolded.
  • Heavy-chain antibodies are immunoglobulins naturally lacking a light chain; they have been identified in species as varying as ca elids and sharks.
  • the variable domains of heavy-chain antibodies can be produced in yeast.
  • hc-Fv variable domains of heavy-chain antibodies
  • a male llama (Lama glama) was immunised with authentic mature chymosin. Immunisations were performed both subcutaneously and intramuscularly using 1 ml 0.125 mg/ml rennin (Sigma) per immunisation site.
  • the first two immunisations were performed with a three week interval and using a water in oil emulsion (9:11 (v/v) antigen in water: specol) as described by Bokhout et al . (1981, Vet. Immunol. Immunopath. 2: 491-500).
  • the third immunisation was done without adjuvant five weeks after the first immunisation.
  • a blood sample of about 200 ml was taken from the immunised llama both at 42 and 77 days after the first immunisation and an enriched lymphocyte population was obtained via Ficoll (Pharmacia) discontinuous gradient centrifugation. From these cells, total RNA was isolated by acid guanidium thiocyanate extraction, after which first strand cDNA synthesis was performed using random ⁇ -mer primers (Amersha first strand cDNA synthesis kit) . DNA fragments encoding hc-Fv fragments and part of either the long or short hinge region were amplified by PCR using respectively primers V H -2B and BOLI 25 or V H -2B and BOLI 26:
  • V H -2B 5 ' -AGGTS ARCTGCAGSAGTCWGG
  • BOLI 25 5 ' -GGAGCTGGGGTCTTCGCTGTGGTGCG
  • BOLI 26 5 ' -TGGTTGTGGTTTTGGTGTCTTGGGTT
  • PCR reactions contained predominantly the PCR fragments encoding the hc-Fv. These fragments were digested with PstI and BstEII and ligated into the multiple cloning site of a suitable plasmid, such as plasmid pUR4585 which is a 2 ⁇ m-derived E. coli -yeast shuttle vector suitable for GAL7- driven expression of antibody fragments fused to the invertase signal peptide and containing C-terminal myc and hexahistidine tags.
  • plasmid pUR4585 is a 2 ⁇ m-derived E. coli -yeast shuttle vector suitable for GAL7- driven expression of antibody fragments fused to the invertase signal peptide and containing C-terminal myc and hexahistidine tags.
  • the four libraries were introduced into a suitable host cell strain, such as yeast strain W303-1A by transformation according to (Klebe et al . , 1983, Gene 25:333-341). At least 2000 colonies of each library were screened for their ability to produce an antibody specific for chymosin using a two membrane system, which is a modification of the procedure described by Skerra et al . (1991, Anal. Bioche . 196:151- 155) .
  • the colonies were transferred from a standard minimal medium plate [0.67% (w/v) Yeast Nitrogen Base without amino acids, 2% (w/v) glucose, 2% (w/v) agar, the relevant amino acids (eacht at 20 mg/1) ] to a minimal medium plate containing 2% (w/v) galactose instead of glucose in order to induce expression of GAL7 -controlled genes.
  • This plate contained a nitro-cellulose membrane (Optitran BA-S 83 membrane, Schleicher and Schuell) and a polycarbonate membrane. After incubation at 30°C for 72 hr the antibody fragments that were secreted by the yeast cells will have diffused through the non binding polycarbonate membrane and will be captured on the nitro-cellulose membrane.
  • the plasmids encoding for these antibody fragments were isolated by plasmid rescue (Robzyk and Kassir, 1992, Nucl . Acids Res. 20: 3790) and after determination of the DNA sequence of the region encoding the antibody fragments the deduced amino acid sequence of the various antibody fragments was compared.
  • the antibody fragments were clearly derived from clonally unrelated B-cells, as was most evident from the variation in both length and sequence of the CDR3 region.
  • EXAMPLE 5 Direct selection of host cells comprising a functional chaperone-like protein by suppression of chymosin expression induced growth inhibition
  • the host cells which express a chaperone-like protein suppress growth inhibition caused by the prochymosin expression and accumulation, thus growth of these host cells expressing the wanted functional chaperone-like protein on galactose plates must result in the immediate detection of colonies of the wanted transformed host cells.
  • the plasmids encoding for these antibody fragments were isolated by plasmid rescue and introduced into wild-type yeast strain W303-1A. The binding of the antibody fragments secreted by these transformants to chymosin was then tested by plate-assay. As can be seen in Table 2, clones C108 and C110 were chymosin binders.
  • MR16 producing the various chymosin binding antibody fragments was then tested for the level of chymosin secretion as compared to YEplacl ⁇ l transformed MR16 using an enzyme assay.
  • C96 and C108 clearly result in an increase in chymosin secretion.
  • These clones are also binders for chymosin, suggesting that the binding of the antibody fragments to chymosin was responsible for the increase in the level of chymosin secretion.
  • Many of the antibody fragments that were initially selected for binding to chymosin do not show a chaperone-like effect on prochymosin secretion, possibly because these antibody fragments are specific for epitope(s) that when bound by antibody do not facilitate protein folding.
  • binding by these antibody fragments could possibly inhibit chymosin enzyme activity, masking a stimulatory effect on prochymosin secretion.
  • Binding of antibody fragments to (pro) chymosin may inhibit the autocatalytic activation of prochymosin and chymosin enzyme activity.
  • the antibody fragments should be removed from the foreign protein in order to obtain a commercially interesting process. This can for example be accomplished by the display of the antibody fragments on the surface of the cells used for expression (reviewed by Georgiou et al . , 1997, Nature Biotechnology 15: 29-34) .
  • the foreign protein can then be separated from the antibody fragment by separation of cells from culture medium under conditions which prevent the antibody from binding to its target.
  • the chaperone-like proteins such as antibody fragments C96 and C108 can be incorporated into the host cell wall by fusion, in the case of yeast cells, to the C-terminal fragment of yeast a-agglutinin, a protein normally present in the yeast cell wall, as has previously been described
  • Transformants of MR16 containing either of these plasmids contain the prochymosin bound to the yeast cell wall when they are induced for heterologous protein expression at neutral pH.
  • the yeast cytosol contains at least 4 different Hsp70-type chaperones.
  • the yeast ER also contains at least 1 other Hsp70-type chaperone, in addition to the well-known BiP (Baxter et al . , 1996, Mai. Cell. Biol . 16: 6444-6456).
  • DNA shuffling (Stemmer, 1994, Nature 370: 389-391) is a method for in vitro homologous recombination of pools of selected mutant genes by random fragmentation and re-assembly of nucleic acid fragments.
  • ER-resident proteins contain specific retention signals that distinguish these proteins from proteins that are destined for further transport towards the cell surface.
  • Lumenal (soluble) proteins of yeast usually contain the lumenally-exposed C-terminal sequence KDEL (a related sequence is present in other species, e.g. HDEL in mammals) that is necessary and sufficient for ER-localization (Munro and Pelham, 1987, Cell 48: 899-907).
  • Fusion of the C-terminal sequence KDEL with the antibody fragments C96 and C108 can be accomplished by plasmid construction, such as inserting the appropriate double strand oligonucleotide into the BstEII and HindiII restriction sites of plasmids pC96L and pC108L.
  • the resulting retention in the ER has the advantage that the concentration of the chaperone-like protein in the ER is higher, which gives a higher potential for chaperone-like protein function. Furthermore, the antibody fragments are not secreted into the culture supernatant together with the foreign protein, where it could inhibit the function of the foreign protein by binding to it.
  • the chaperone-like protein determines whether it can function as a chaperone it can be determined which of the various specific fragments recognises a different site (epitope) by performing competitive inhibition ELISA (e.g. Kaveri , 1995, Epitope and idiotope mapping using monoclonal antibodies. In: Paul (Ed.), Antibody Engineering Protocols, Humana Press Inc., Totowa, NJ, PP. 171-181) .
  • competitive inhibition ELISA e.g. Kaveri , 1995, Epitope and idiotope mapping using monoclonal antibodies. In: Paul (Ed.), Antibody Engineering Protocols, Humana Press Inc., Totowa, NJ, PP. 171-181) .
  • a chaperone-like protein could function by binding to a folding intermediate instead of to the authentic correctly folded protein. Since most antibodies obtained after immunisation recognise only the correctly folded protein but not the misfolded protein or folding intermediates, the isolation of chaperone-like proteins by selection of antibodies from immunised organisms may not be optimal. However, in order to obtain a specifically binding antibody fragment it is not necessary to immunise an organism. Large libraries of antibody fragments have been constructed from unimmunised organisms which contain a very diverse set of binding fragments. Antibody fragments binding to any desired target ligand can be isolated from such libraries (Vaughan et al . , 1996, Nature Biotechnology 14, 309-314).
  • Such so-called random libraries are constructed by either randomisation of the regions of the variable antibody domains that are involved in antigen binding, the complementarity- determining regions, or by the cloning of a very large number of unselected antibody fragments, or by a combination of these methods.
  • Antibody fragments derived from such random libraries can also have a chaperone-like function.
  • Novel binding proteins can be obtained by the randomization of surface residues of a parenteral protein molecule that itself does not have the required binding specificity, but which has a known 3D-structure that can be used as a scaffold (reviewed in Nygren and Uhlen, 1997, Current Opinion in Structural Biology 7:463-469).
  • binding proteins can be selected from libraries via specific binding towards a desired target ligand and have the potential to replace natural antibodies or antibody fragments.
  • binding proteins have been isolated after randomization of, for example, the Z-domain of protein A
  • artificial binding domains can also be used as a chaperone-like protein.
  • the artificial binding domains can be isolated by randomization and expression using a phage display vector in Escherichia coli as has been described in the above mentioned references, selection for binding to the desired heterologous protein, followed by selection for specifically binding fragments that have a chaperone-like function.
  • the specifically binding fragment can be directly selected for its chaperone-like function by suppression of heterologous protein expression induced growth inhibition, as was described above.
  • plasmid pRL43 For the expression of a random library of artificial binding domains of the Z-domain of protein A in yeast a suitable vector, such as plasmid pRL43 can be derived from plasmid pUR4585 in several steps (see Figure 2) .
  • a Bglll restriction site can be introduced into the region encoding the invertase signal peptide by inserting a synthetically prepared double stranded DNA fragment into the SacI and PstI sites of plasmid pUR4585.
  • yeast cells expressing a heterologous protein that is deleterious for cell growth such as strain MR16 (see above) using an efficient transformation protocol, such' as lithium acetate- transformation (Ito et al . , 1983, J. Bacteriol . 153: 163- 168) .
  • Yeast cells containing the wanted chaperone-like protein can then be selected as described above.
  • FIG. 1 Insert of plasmid pUR4585 which is suitable for expression of a fusion protein between the yeast invertase signal peptide (single underlined) , a llama heavy-chain antibody fragment (italicized) , a myc tail (bold) and a hexahistidine tail (double underlined) in yeast.
  • Heavy-chain antibodies should be inserted as PstI and BstEII restriction fragments into this vector. These restriction enzymes cut in the beginning and end of heavy chain antibodies. Therefore, the first 5 amino acids (sequence QVQLQ) and the last 6 amino acids (sequence QVTVSS) are encoded by this vector. Only relevant restriction sites are indicated.
  • FIG. 1 Insert of plasmid pRL43 encoding a fusion protein consisting of the invertase signal peptide (underlined) and the Z-domain of protein A.
  • the codons for the amino acids that are used for randomisation are underlined.
  • the former HindiII restriction site of plasmid pUR4585 that was destroyed in the construction of pRL43 is indicated in bold.
  • yeast strain MR16 After transformation of yeast strain MR16 with the indicated libraries or control plasmid YEplacl ⁇ l the cells were spread on plates containing either glucose, which suppresses chymosin expression, or galactose, which induces chymosin expression.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à la fabrication de protéines recombinantes exprimées dans des cellules hôtes hétérologues et à des procédés permettant d'accroître la fabrication de ces protéines au moyen d'une protéine du type chaperone. Fabriquer ou isoler une protéine ou un polypeptide, en grandes quantités et sous une forme relativement pure, à partir de son hôte ou de sa cellule hôte (homologue) d'origine dans lequel la protéine ou le polypeptide est exprimé, est lourd et souvent inintéressant du point de vue économique. Néanmoins, le développement de la technique de l'ADN recombinant a ouvert la voie à la fabrication de protéines au moyen de leur expression, par exemple, dans un hôte ou une cellule hôte hétérologue. Un ensemble de polypeptides ou protéines exogènes peuvent désormais être produits ou exprimés dans des systèmes d'expression hétérologues. Cet ensemble est vaste et continue de se développer. Cette invention concerne un procédé permettant d'exprimer un polypeptide codé par une séquence d'acides nucléiques présente dans une cellule hôte qui renferme, en outre, une protéine du type chaperone susceptible de se lier de manière spécifique audit polypeptide.
PCT/NL1998/000335 1997-06-13 1998-06-08 Production accrue de proteines au moyen de proteines du type chaperone WO1998056928A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU80407/98A AU8040798A (en) 1997-06-13 1998-06-08 Increased production of proteins by using chaperone-like proteins
EP98928658A EP0980436A1 (fr) 1997-06-13 1998-06-08 Production accrue de proteines au moyen de proteines du type chaperone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97201790 1997-06-13
EP97201790.9 1997-06-13

Publications (1)

Publication Number Publication Date
WO1998056928A1 true WO1998056928A1 (fr) 1998-12-17

Family

ID=8228437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1998/000335 WO1998056928A1 (fr) 1997-06-13 1998-06-08 Production accrue de proteines au moyen de proteines du type chaperone

Country Status (3)

Country Link
EP (1) EP0980436A1 (fr)
AU (1) AU8040798A (fr)
WO (1) WO1998056928A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001048227A1 (fr) * 1999-12-23 2001-07-05 Genencor International, Inc. Methodes de production de proteines dans des cellules hotes
EP1134231A1 (fr) * 2000-03-14 2001-09-19 Unilever N.V. Domaines variables de la chaine lourde d'anticorps contre des enzymes humaines alimentaires et leurs utilisations
WO2003061570A2 (fr) * 2002-01-16 2003-07-31 Zyomyx, Inc. Proteines de liaison transgeniques
US8252551B2 (en) 2003-12-23 2012-08-28 Novozymes Biopharma Dk A/S 2-micron family plasmid and use thereof
US8969064B2 (en) 2003-12-23 2015-03-03 Novozymes Biopharma Dk A/S Gene expression technique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GETHING M -J ET AL: "BINDING SITES FOR HSP70 MOLECULAR CHAPERONES IN NATURAL PROTEINS", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, vol. 60, 1995, pages 417 - 428, XP000613691 *
HARMSEN, M. M. ET AL: "Overexpression of binding protein and disruption of the PMR1 gene synergistically stimulate secretion of bovine prochymosin but not plant thaumatin in yeast", APPL. MICROBIOL. BIOTECHNOL. (1996), 46(4), 365-370 CODEN: AMBIDG;ISSN: 0175-7598, 1996, XP002045333 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001048227A1 (fr) * 1999-12-23 2001-07-05 Genencor International, Inc. Methodes de production de proteines dans des cellules hotes
US6677139B1 (en) 1999-12-23 2004-01-13 Genecor International, Inc. Methods for production of proteins in host cells
EP1134231A1 (fr) * 2000-03-14 2001-09-19 Unilever N.V. Domaines variables de la chaine lourde d'anticorps contre des enzymes humaines alimentaires et leurs utilisations
US7361741B2 (en) 2000-03-14 2008-04-22 Lipton, Division Of Conopco, Inc. Antibody, or fragment thereof, capable of binding specifically to human pancreatic lipase
WO2003061570A2 (fr) * 2002-01-16 2003-07-31 Zyomyx, Inc. Proteines de liaison transgeniques
WO2003061570A3 (fr) * 2002-01-16 2003-09-18 Zyomyx Inc Proteines de liaison transgeniques
US8252551B2 (en) 2003-12-23 2012-08-28 Novozymes Biopharma Dk A/S 2-micron family plasmid and use thereof
US8969064B2 (en) 2003-12-23 2015-03-03 Novozymes Biopharma Dk A/S Gene expression technique
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique

Also Published As

Publication number Publication date
AU8040798A (en) 1998-12-30
EP0980436A1 (fr) 2000-02-23

Similar Documents

Publication Publication Date Title
Stein et al. The single translation product of the FUM1 gene (fumarase) is processed in mitochondria before being distributed between the cytosol and mitochondria in Saccharomyces cerevisiae
JP3068139B2 (ja) 酵母よりヒト血清アルブミンおよびその他の異種蛋白質を微生物学的に生産する方法
EP0366400B1 (fr) ADN codant pour le sérum albumine humain (SAH), plasmides et hÔtes contenant cet ADN et production de SAH
JP2980626B2 (ja) ペクチン酸リアーゼのシグナル配列を含む新規プラスミドベクター
Kipriyanov et al. High level production of soluble single chain antibodies in small-scale Escherichia coli cultures
US6924125B2 (en) Expression of heterologous multi-domain proteins in yeast
JP3691055B2 (ja) 特異的結合力をもつ固定化タンパク質並びに各種プロセス・物品におけるそれらの使用
FI81379B (fi) Anvaendning av kluyveromyces-jaest saosom vaerd foer transformering och uttryckning av fraemmande gener.
EP1134231B1 (fr) Domaines variables de la chaine lourde d'anticorps contre des lipases humaines alimentaires et leurs utilisations
JP3542604B2 (ja) Ｙａｐ３シグナルペプチドをコードするｄｎａ構築体
EP0848756B1 (fr) Materiels et procedes relatifs a la fixation et a la presentation de substances sur des surfaces cellulaires
JPS59205997A (ja) ヒト−インシユリン様成長因子の製造方法
Emr et al. Molecular components of the signal sequence that function in the initiation of protein export.
CN112955547A (zh) 通过使用转录因子来增加蛋白质表达的手段和方法
WO1988002779A1 (fr) Vecteurs composites de levure
AP80A (en) Expression of HIV binding proteins.
WO1998056928A1 (fr) Production accrue de proteines au moyen de proteines du type chaperone
JPH02501108A (ja) 微生物によるヒト副甲状腺ホルモンの生産
JPH04339259A (ja) 突然変異菌株の検出法
US6265545B1 (en) Reading frame independent epitope tagging
JP4180112B2 (ja) 酵母細胞におけるｎ末端を伸長されたタンパクの発現のためのベクター
EP0698097B1 (fr) Production d'anticorps ou de fragments fonctionnalises d'anticorps, derives des immunoglobulines a chaine lourde de camelidae
JP2540039B2 (ja) プラスミドベクタ−
WO1995022614A1 (fr) Production de proteines recombinees ancrees par glycosylphosphatidylinositol
JPH09505998A (ja) ブタ膵臓カルボキシペプチダーゼｂをコードするｄｎａ配列

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09460037

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998928658

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998928658

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999502151

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998928658

Country of ref document: EP